Hemoglobinopathies  >>  Lucentis (ranibizumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lucentis (ranibizumab) / Roche, Novartis
NCT00618644: Ranibizumab for Neovascularization in Sickle Cell Retinopathy

Withdrawn
1
0
US
Ranibizumab, Lucentis (ranibizumab)
Kresge Eye Institute, Wayne State University, Genentech, Inc.
Sickle Cell Anemia, Retinopathy
06/11
06/11

Download Options